Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN033 in advanced non-small cell lung cancer
NCT07283198Phase 2Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of JSKN033 in non-small cell lung cancer (NSCLC), sponsored by Alphamab Oncology. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
JSKN033
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07283198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283198.